[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-partum-women\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-partum-women":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642193","restrictions-on-maternity-ward-visits-current-situation-challenges-and-recommendations-in-the-auvergne-rhone-alpes-region-aura-100642193",false,"NCT07653646","Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the Auvergne Rhone-Alpes Region (AuRA)","Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the AuRA Region","VISIMAT","Inclusion Criteria:\n\n* Adult female patient (aged 18 or over),\n* Female patient admitted to the maternity ward with her newborn baby or babies,\n* Length of stay in the maternity ward of 48 hours or more,\n* Female patient who has been informed about the study and has given her free, informed verbal consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who have already participated in this study,\n* Patients whose newborn(s) are hospitalised in neonatal units, neonatal intensive care units or neonatal resuscitation units,\n* Patients who have given birth to three or more newborns (triplets or more),\n* Patient whose newborn(s) has\u002Fhave died,\n* Patient unable to understand spoken or written French, making self-assessment impossible,\n* Patient under guardianship, curatorship or placed under judicial protection,\n* Patient not covered by the French social security system.","FEMALE","18 Years",{"count":20,"type":21},8000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Between 2016 and 2018, suicide was also the leading cause of maternal mortality in the year following childbirth, underscoring the severity and frequency of these disorders. In response, international guidelines, notably those of the World health Organisation (WHO), as well as national policies such as the 'First 1,000 Days' strategy, emphasise the importance of early, enhanced and individualised postnatal support. In France, this postpartum care tends to be structured around the Early Postnatal Interview and the recommended use of validated screening tools such as the Edinburgh Postnatal Depression Scale (EPDS).\n\nHowever, the quality of postpartum care depends not only on screening and clinical follow-up, but also on organisational and environmental factors. Among these, the arrangements for maternity ward visits constitute a potential determinant of patients' experiences, likely to influence both their mental state, their rest, the establishment of breastfeeding and, indirectly, the health of the newborn. The exceptional measures implemented during the Covid-19 pandemic, notably the restriction of visits, have shown generally favourable effects, with improved satisfaction among patients and healthcare staff, better conditions for rest, facilitation of breastfeeding and a perceived improvement in working conditions.\n\nHowever, these data were collected in an exceptional health context, which may introduce biases linked to the social, emotional and organisational constraints specific to this period. Their extrapolation to routine practice therefore remains uncertain. Furthermore, in the absence of specific national guidelines governing maternity ward visits, the current regulatory framework remains unclear and practices vary between institutions, often relying on local decisions that have not been scientifically evaluated.\n\nAgainst this backdrop, the VISIMAT study aims to characterise maternity ward visiting arrangements outside of any exceptional circumstances and to assess their impact on the health of mothers and newborns, as well as on healthcare workers' working conditions. Its aim is to provide a scientific basis to inform the development of standardised recommendations and prevention messages.",[27,28],"Post Partum Women","Newborn Health",[30,31,32],"maternity wards visiting","mother health","newborn health","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2028-06",{"name":43,"class":44},"Centre Hospitalier Annecy Genevois","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100581062","phase-4-prevention-of-postpartum-venous-thromboembolism-in-women-at-intermediate-risk-100581062","NCT06845423","Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk. An Open-label, Randomized, Controlled Trial Comparing Two Strategies With or Without Pharmacological Thromboprophylaxis","MUM-VTE","Inclusion Criteria:\n\n* Women at intermediate risk of VTE during post-partum= with a 3% or more risk of VTE based on a validated prediction model\\* or International guidelines (ACCP 2012).\n* Age over 18 years\n* Delivery between 6 hours and \\\u003C 36 hours\n* Written informed consent\n\n  * Definition: Intermediate risk is defined as ≥ 3%, based on risk prediction model developed by Sultan et al taking in account: smoking, varicose veins, obesity, comorbidities, diabetes, pre-eclampsia, post-partum hemorrhage, postpartum infection, emergency or elective section or following ACCP guidelines: one major risk factor or two minor risk factors.\n\nExclusion Criteria:\n\n* Previous personal history of VTE\n* LMWH started during antenatal period\n* Need for anticoagulation at curative dose\n* Contraindication to LMWH (previous heparin induced thrombopenia, hemostatic impairment, known severe renal insufficiency)\n* Women who received more than two doses of LMWH since delivery\n* Unable or refusal to give informed consent\n* Aspirin at a daily dose 100 mg or dual antiplatelet therapy\n* Previous inclusion in Mum-VTE study\n* Concomitant participation in another therapeutic study",{"count":55,"type":21},2400,[57],"PHASE4","Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4\u002F1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths.\n\nMajority of postpartum VTE occurs in women with one or more moderate risk factors (obesity, caesarean section, postpartum hemorrhage). For these women at intermediate risk, the efficacy and safety of thromboprophylaxis have not been assessed yet during postpartum and international guidelines for pharmacological thromboprophylaxis, based on data extrapolated from other populations, observational studies and small clinical trials are inconsistent across countries.\n\nWe designed an open-label, randomized, controlled trial, aiming to demonstrate the superiority of a pharmacological thromboprophylaxis strategy with LMWH (LMWH type chosen according to physician \u002F patient's preference) during 6 weeks after delivery (the 6-weeks follow-up visit being matched with usual care) in women at intermediate risk, over no pharmacological thromboprophylaxis.",[60,27],"Venous Thromboembolism (VTE)","RECRUITING","2026-06-09",{"date":64,"type":37},"2026-06-10",{"date":66,"type":37},"2025-05-16",{"date":68,"type":21},"2028-08-16",{"name":70,"class":44},"University Hospital, Brest",18,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100518528","fetal-cell-receptors-repertoire-100518528","NCT06031714","Fetal Cell Receptors Repertoire","\"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial\"","MoreCCR","Inclusion Criteria:\n\nCommon criteria :\n\n* Adult women,\n* Post-partum: having been pregnant for any length of time,\n* Having signed a free and informed consent form,\n* Primiparous or multiparous,\n* Affiliated to a health insurance\n\nPatients :\n\n\\- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer\n\nControl group patients :\n\n* Volunteers,\n* Age-matched,\n* Without skin ulcers.\n\nThere are no specific criteria for children.\n\nExclusion Criteria:\n\n* Minors (for patients)\n* Under court protection, curatorship, guardianship (for patients)\n* Immunocompromised patients for any reason whatsoever\n* Refusal of consent\n* Refusal of blood and\u002For saliva samples for themselves or a member of their family",true,"ALL",{"count":83,"type":21},160,[24],"The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.",[87,88,89,90,91],"Venous Ulcer","Sickle Cell Ulcer","Diabetic Ulcer","Post-partum Women","Mixed Ulcer",[93,94,95],"Microchimerism","Foetal stem cells","Receptors","2025-09-05",{"date":98,"type":37},"2025-09-12",{"date":100,"type":37},"2024-02-06",{"date":102,"type":21},"2027-02-01",{"name":104,"class":44},"Assistance Publique - Hôpitaux de Paris"]